已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial

医学 内科学 安慰剂 双盲 溃疡性结肠炎 胃肠病学 姜黄素 盲法研究 随机对照试验 药理学 病理 疾病 替代医学
作者
Shomron Ben‐Horin,Nir Salomon,Georgios Karampekos,Nikos Viazis,Adi Lahat,Bella Ungar,Rami Eliakim,Rafael Kuperstein,Ofra Kriger-Sharabi,Hilla Reiss Mintz,Henit A. Yanai,Iris Dotan,Eran Zittan,Nitsan Maharshak,Ayal Hirsch,Michal Weitman,Gerassimos J. Mantzaris,Uri Kopylov
出处
期刊:Clinical Gastroenterology and Hepatology [Elsevier BV]
卷期号:22 (2): 347-356.e6 被引量:80
标识
DOI:10.1016/j.cgh.2023.05.023
摘要

Background & AimsWe evaluated the efficacy of herbal combination of curcumin-QingDai (CurQD) in active ulcerative colitis (UC).MethodsPart I was an open-label trial of CurQD in patients with active UC, defined by a Simple Clinical Colitis Activity Index score of 5 or higher and a Mayo endoscopic subscore of 2 or higher. Part II was a placebo-controlled trial conducted in Israel and Greece, randomizing active UC patients at a 2:1 ratio to enteric-coated CurQD 3 g/d or placebo for 8 weeks. The co-primary outcome was clinical response (reduction in the Simple Clinical Colitis Activity Index of ≥3 points) and an objective response (Mayo endoscopic subscore improvement of ≥1 or a 50% fecal calprotectin reduction). Responding patients continued either maintenance curcumin or placebo alone for an additional 8 weeks. Aryl-hydrocarbon receptor activation was assessed by cytochrome P450 1A1 (CYP1A1) mucosal expression.ResultsIn part I, 7 of 10 patients responded and 3 of 10 achieved clinical remission. Of 42 patients in part II, the week 8 co-primary outcome was achieved in 43% and 8% of CurQD and placebo patients, respectively (P = .033). Clinical response was observed in 85.7% vs 30.7% (P < .001), clinical remission in 14 of 28 (50%) vs 1 of 13 (8%; P = .01), a 50% calprotectin reduction in 46.4% vs 15.4% (P = .08), and endoscopic improvement in 75% vs 20% (P = .036) in the CurQD and placebo groups, respectively. Adverse events were comparable between groups. By week 16, curcumin-maintained clinical response, clinical remission, and clinical biomarker response rates were 93%, 80%, and 40%, respectively. CurQD uniquely up-regulated mucosal CYP1A1 expression, which was not observed among patients receiving placebo, mesalamine, or biologics.ConclusionsIn this placebo-controlled trial, CurQD was effective for inducing response and remission in active UC patients. The aryl-hydrocarbon receptor pathway may merit further study as a potential UC treatment target. ClinicalTrials.gov ID: NCT03720002.Graphical abstract
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
不灵0发布了新的文献求助10
2秒前
2秒前
3秒前
4秒前
5秒前
5秒前
6秒前
11完成签到,获得积分10
6秒前
jinlin发布了新的文献求助10
6秒前
7秒前
SYX发布了新的文献求助10
8秒前
8秒前
9秒前
徐徐发布了新的文献求助10
9秒前
长情语蕊发布了新的文献求助30
9秒前
lll完成签到,获得积分20
10秒前
10秒前
滴嘟完成签到,获得积分10
11秒前
11秒前
11秒前
上官若男的应助被汪进辉_Will采纳,获得10
11秒前
12秒前
Ebony完成签到,获得积分10
12秒前
14秒前
14秒前
15秒前
15秒前
彭于晏的应助被快乐的心情采纳,获得10
16秒前
SYX完成签到,获得积分10
16秒前
16秒前
xiezhihao发布了新的文献求助10
16秒前
传奇3的应助被滴嘟采纳,获得10
16秒前
zhhyi1976发布了新的文献求助10
17秒前
传奇3的应助被夏侯乌采纳,获得10
17秒前
浩懿一发布了新的文献求助10
19秒前
19秒前
圈圈发布了新的文献求助10
21秒前
过度干涉完成签到 ,获得积分10
21秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184619
求助须知:如何正确求助?哪些是违规求助? 9573576
关于积分的说明 21832380
捐赠科研通 7781845
什么是DOI,文献DOI怎么找? 3434399
关于科研通互助平台的介绍 2558498
邀请新用户注册赠送积分活动 2481003